Ignite Creation Date:
2025-12-25 @ 4:25 AM
Ignite Modification Date:
2025-12-26 @ 3:28 AM
Study NCT ID:
NCT05452720
Status:
RECRUITING
Last Update Posted:
2024-11-06
First Post:
2022-07-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
MASA Valve Early Feasibility Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D013771', 'term': 'Tetralogy of Fallot'}, {'id': 'D011666', 'term': 'Pulmonary Valve Stenosis'}, {'id': 'D014339', 'term': 'Truncus Arteriosus, Persistent'}, {'id': 'D014188', 'term': 'Transposition of Great Vessels'}, {'id': 'D018633', 'term': 'Pulmonary Atresia'}], 'ancestors': [{'id': 'D006330', 'term': 'Heart Defects, Congenital'}, {'id': 'D018376', 'term': 'Cardiovascular Abnormalities'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D000013', 'term': 'Congenital Abnormalities'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D006349', 'term': 'Heart Valve Diseases'}, {'id': 'D014694', 'term': 'Ventricular Outflow Obstruction'}, {'id': 'D001028', 'term': 'Aortopulmonary Septal Defect'}, {'id': 'D006343', 'term': 'Heart Septal Defects'}, {'id': 'D054079', 'term': 'Vascular Malformations'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DEVICE_FEASIBILITY', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'The MASA Valve Early Feasibility Study (MVEFS) is a multi-center, non-randomized, prospective, interventional clinical study to determine the safety and probable benefit of MASA Valve pulmonary valved conduit in the indicated subset of patients requiring Right Ventricular Outflow Tract Reconstruction (RVOTR).\n\nEach implanted subject will be consented to be followed for a total of 5 years with a post-op, 30 day (30+7), 180 day (180±30) and 1 year follow-up (365 ± 90 days) followed by an annual follow up until 5 years (annual visits with a window of ± 90 days per visit), or until trial closure. Total expected duration of the trial is approximately 5 year from the last enrolled patient. Intermediary results of the trial may be calculated prior to completion of the 1-year (365 ± 90 days) endpoint of all patients.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 10}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-05-18', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-11', 'completionDateStruct': {'date': '2028-04-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-11-04', 'studyFirstSubmitDate': '2022-07-06', 'studyFirstSubmitQcDate': '2022-07-06', 'lastUpdatePostDateStruct': {'date': '2024-11-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-07-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-04-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Freedom from device related death', 'timeFrame': '1 year', 'description': 'Percentage of patients that have not died related to the device 1 year from implantation'}, {'measure': 'Freedom from Explant', 'timeFrame': '1 year', 'description': 'Percentage of patients that have not undergone device explant within 1 year from implantation'}, {'measure': 'Freedom from Device-Related Reoperation', 'timeFrame': '1 year', 'description': 'Percentage of patients that have not undergone re-operation related to the device within 1 year from implantation'}, {'measure': 'Freedom from Device-Related Catheter Intervention', 'timeFrame': '1 year', 'description': 'Percentage of patients that have not undergone device related catheter based intervention within 1 year from implantation'}, {'measure': 'Freedom from Endocarditis', 'timeFrame': '1 year', 'description': 'Percentage of patients that have not had endocarditis within 1 year from implantation'}, {'measure': 'Freedom from Thrombus', 'timeFrame': '1 year', 'description': 'Percentage of patients that have not had a serious thrombotic event related to the device within 1 year from implantation'}, {'measure': 'Freedom from Major Hemorrhage', 'timeFrame': '1 year', 'description': 'Percentage of patients that have not had a major bleeding episode related to the device within 1 year from implantation'}], 'secondaryOutcomes': [{'measure': 'Freedom from Moderate or Greater Pulmonary Regurgitation', 'timeFrame': '1 year', 'description': 'Percentage of patients that show less than Moderate Pulmonary Regurgitation within 1 year from implantation on Echocardiographic assessment'}, {'measure': 'Freedom from Pulmonary Gradient ≥36mmHg', 'timeFrame': '1 year', 'description': 'Percentage of patients that have a Pulmonary Gradient \\<= 36mmHg within 1 year from implantation on Echocardiographic assessment'}, {'measure': 'Freedom from device valve failure', 'timeFrame': '1 year', 'description': 'Percentage of patients that show do not show valve functional failure on Echocardiographic assessment'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isUnapprovedDevice': True, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['Right Ventricular Outflow Tract Reconstruction', 'Pulmonary Valve', 'MASA Valve', 'Pulmonary Valve Replacement'], 'conditions': ['Tetrology of Fallot', 'Pulmonary Stenosis', 'Truncus Arteriosus', 'Transposition of Great Vessels', 'Pulmonary Atresia', 'Ross Procedure']}, 'descriptionModule': {'briefSummary': 'The MASA Valve Early Feasibility Study (MVEFS) multi-site interventional clinical trial within the United States of America with each center following a common protocol.The objective of the trial is to evaluate the safety and probable benefit of MASA Valve in the indicated subset of patients requiring Right Ventricular Outflow Tract Reconstruction (RVOTR). As an early feasibility study, the purpose is determine the feasibility of success of the device in order to gather early data towards a future pivotal study and/or regulatory clearance submission.', 'detailedDescription': 'The MASA Valve is a bi-leaflet pulmonary valved conduit. The MASA Valve has an ePTFE conduit and ePTFE leaflets fixtured to the conduit with polypropylene suture. The device has a pad-printed design on the outer conduit surface indicating the valve position and direction of flow. .\n\nThe MASA Valve is intended to be used to reconstruction the Right Ventricular Outflow Tract (RVOT) and provide a functional pulmonary valve. Once implanted, the MASA Valve provides a pathway for blood from the Right Ventricle (RV) to the Pulmonary Arteries (PAs), while the integrated valve helps to prevent backflow into the RV. The MASA Valve Indications for Use are:\n\nThe MASA Valve pulmonary valved conduit is indicated for correction or reconstruction of the right ventricular outflow tract (RVOT) in patients aged less than 22 years with any of the following congenital cardiac malformations:\n\n* Pulmonary Stenosis\n* Tetralogy of Fallot\n* Truncus Arteriosus\n* Transposition of Great Vessels\n* Pulmonary Atresia\n\nIn addition, the MASA Valve is indicated for the replacement of previously implanted, but dysfunctional, pulmonary valves, valved conduits or conduits, as well as for use in the Ross Procedure when the native RVOT is being used to reconstruct the Aorta.\n\nTreatments currently available for the above-stated conditions include biologic-tissue-based valved conduits (Homografts and Contegra Glutaraldehyde-fixed Bovine Jugular Vein), Intra-operatively constructed valved conduits made from off-the-shelf vascular grafts and cardiovascular membranes, and non-valved cardiovascular conduits. Based on existing evidence it is believed the potential benefits of MASA Valve outweigh the potential risks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '22 Years', 'minimumAge': '0 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. At least one of the following: Right Ventricular to Pulmonary Artery mean gradient \\> 35mm Hg, moderate or severe Pulmonary regurgitation (≥3+), or clinical indication for replacement of their native or prosthetic pulmonary valve with a prosthesis.\n2. Age \\< 22 years\n3. Patient is geographically stable and willing to return for 1 year follow-up for the trial.\n4. Patient's legal guardian should be willing to provide informed consent (IC) at the hospital location where they are being enrolled.\n5. The patient, and the patient's parent / legal representative where appropriate, and the treating physician agree that the subject will return for all required post-procedure follow up visits and the subject will comply with clinical investigation plan required follow-up visits.\n\nExclusion Criteria:\n\n1. Patient is in need of or has presence of a prosthetic heart valve at any other position\n2. Patient has a need for concomitant surgical procedures (non-cardiac)\n3. Patients with previously implanted pacemaker (including defibrillators) or mechanical valves\n4. Patient has an active bacterial or viral infection or requiring current antibiotic therapy (if temporary illness, patient may be a candidate 4 weeks after discontinuation of antibiotics)\n5. Patient has an active endocarditis\n6. Leukopenia, according to local laboratory evaluation of white blood cell count\n7. Acute or chronic anemia, according to local laboratory evaluation of hemoglobin Patients can be transfused to meet eligibility criteria\n8. Thrombocytopenia, defined as Platelet count \\< 150,000/mm3 Patients can be transfused to meet eligibility criteria\n9. Severe chest wall deformity, which would preclude placement of the PV conduit\n10. Known hypersensitivity to anticoagulants and antiplatelet drugs and to the device materials\n11. Immunocompromised patient defined as: autoimmune disease, patients receiving immunosuppressant drugs or immune stimulant drugs\n12. Patient has chronic inflammatory / autoimmune disease\n13. Need for emergency cardiac or vascular surgery or intervention\n14. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year\n15. Currently participating, or participated within the last 30 days, in an investigational drug or device study\n16. Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months\n17. Patient has medical, social or psychosocial factors that, in the opinion of the Investigator, could have impact on safety or compliance"}, 'identificationModule': {'nctId': 'NCT05452720', 'acronym': 'MVEFS', 'briefTitle': 'MASA Valve Early Feasibility Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'PECA Labs'}, 'officialTitle': 'MASA Valve Early Feasibility Study', 'orgStudyIdInfo': {'id': 'G220040'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Experimental Arm', 'description': 'This is a single-arm study. All participants in this study will undergo implantation with MASA Valve.', 'interventionNames': ['Device: Surgical Right Ventricular Outflow Tract Reconstruction']}], 'interventions': [{'name': 'Surgical Right Ventricular Outflow Tract Reconstruction', 'type': 'DEVICE', 'description': 'Surgical replacement of the Pulmonary Valve or a previously implanted prosthetic with the investigational device (MASA Valve)', 'armGroupLabels': ['Experimental Arm']}]}, 'contactsLocationsModule': {'locations': [{'zip': '61637', 'city': 'Peoria', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Drewann Whalen', 'role': 'CONTACT', 'email': 'Drewann.S.Whalen@osfhealthcare.org', 'phone': '217-714-6496'}, {'name': 'Harma Terbendian, MD', 'role': 'CONTACT'}], 'facility': 'OSF Childrens Hospital of Illinois', 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'David Hoganson, MD', 'role': 'CONTACT', 'email': 'David.Hoganson@cardio.chboston.org', 'phone': '3146106063'}], 'facility': 'Boston Childrens Hospital', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '45229', 'city': 'Cincinnati', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Joshua Freytag', 'role': 'CONTACT', 'email': 'Joshua.Freytag@cchmc.org', 'phone': '513-803-1910'}, {'name': 'David Morales, MD', 'role': 'CONTACT'}], 'facility': "Cincinnati Children's Hospital", 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'William Gaynor, MD', 'role': 'CONTACT', 'email': 'gaynor@chop.edu'}], 'facility': 'Childrens Hospital of Philadelphia', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '75235', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Kara Lorduy', 'role': 'CONTACT', 'email': 'Kara.Lorduy@childrens.com'}, {'name': 'Karl Reyes, MD', 'role': 'CONTACT'}], 'facility': 'Childrens Medical Center Dallas', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}], 'centralContacts': [{'name': 'Arush Kalra, MBBS, MS', 'role': 'CONTACT', 'email': 'arush@pecalabs.com', 'phone': '4123300746'}, {'name': 'Doug Bernstein, BS', 'role': 'CONTACT', 'email': 'doug@pecalabs.com', 'phone': '4125899847'}], 'overallOfficials': [{'name': 'David Morales, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Cinncinnati Childrens Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED', 'description': 'Only anonymized data is intended to be shared with other clinicians.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'PECA Labs', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}